Results 91 to 100 of about 49,818 (236)
Computational and Systems Oncology, Volume 6, Issue 1, December 2026.ABSTRACT Resistance to chemotherapy, which is demonstrated in almost every patient with advanced‐stage lung cancer (ALC), underscores an urgent need to unravel the underlying molecular mechanisms and identify novel strategies to overcome drug resistance. In the present study, an attempt was made to identify epigenetic targets and modulators that can be
Okibur Rahman +2 more
wiley +1 more source
Marcadores moleculares associados ao câncer de mama não metástico
Revista Brasileira de Cancerologia, 2002 O câncer de mama é considerado a mais freqüente neoplasia que acomete mulheres em todo o mundo. No Brasil, representa a primeira neoplasia em incidência na mulher, sendo que a maioria dos casos relatados encontra-se na região Sul (67%).
Daniela de Melo e Silva +2 more
doaj +1 more source
CMBs carrying PTX and CRISPR/Cas9 targeting C‑erbB‑2 plasmids interfere with endometrial cancer cells. [PDF]
Mol Med Rep, 2021 Peng S, Cai J, Bao S.
europepmc +1 more source
Molecular Oncology, Volume 20, Issue 5, Page 1185-1201, May 2026.ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang +8 more
wiley +1 more source
Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes [PDF]
, 2008 Sorbtional properties of carbonic sorbents on the base of pine sawdust in the processes of purification of water mediums and complicated technological solution from petroleum products and phosphorus compounds are investigated.
Mitsugu Kochi +9 more
core +3 more sources
c-erbB-2 protein expression in node negative breast cancer
Annals of Oncology, 1990 We investigated the expression of c-erB-2 protein in two matched groups of breast cancer patients, one with and one without relapse. 37 patients with relapse were compared with 42 patients without recurrence for time of observation, adjuvant treatment, age, menopausal status and estrogen receptor content.
J, Richner +8 more
openaire +2 more sources
Molecular Oncology, Volume 20, Issue 5, Page 1323-1346, May 2026.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
A clinicopathologic study on triple-negative breast cancer patients: HUSM experience [PDF]
, 2011 Breast cancer is the most common cancer among Malaysian women. There are many prognostic factors contributing to the disease and the outcome of the patients.
Saidin, Usman Sani
core
Emerging strategies to target metastasis and therapy resistance in melanoma
Molecular Oncology, Volume 20, Issue 5, Page 1111-1114, May 2026.Emerging studies propose new approaches to interfere with melanoma progression. In recognition of melanoma awareness month, at Molecular Oncology, we highlight recently published research articles, focusing on novel therapeutic targets driving metastatic spread and outlining different strategies to overcome resistance to BRAF inhibitors and anti‐PD‐1 ...
Amel Aziba
wiley +1 more source
Analytical Cellular Pathology, 2000 Amplifiction of the Her-2/neu gene is accompanied by overexpression of its cell surface receptor product, c‐erbB‐2 protein. To investigate the degree of intratumoural heterogeneity we applied immunohistochemistry in primary Barrett’s adenocarcinoma (BCA)
Axel Walch +8 more
doaj +1 more source